999 The PTPN2/N1 small molecule inhibitor ABBV-CLS-484 promotes NK cell activity driving primary tumor regression and preventing metastasis

Chirag Patel; Kathleen A McGuire; Hakimeh Ebrahimi-Nik; Meng Sun; Yue Liu; Kelly Klinge; Jacqueline Aguado; Audrey J Muscato; Payal Tiwari; Omar Avila-Monge; Kayla J Colvin; Kira Olander; Kyle Halliwill; Joseph Klahn; Alexander Schutte; Marcia N Paddock; Jonathan Powell; Keith M Hamel; Jennifer M Frost; Kathleen B Yates; Philip R Kym; Robert T Manguso; Christina K Baumgartner

doi:10.1136/jitc-2023-SITC2023.0999

Article info

Regular and Young Investigator Award Abstracts

Immune Cell Types and Biology

999 The PTPN2/N1 small molecule inhibitor ABBV-CLS-484 promotes NK cell activity driving primary tumor regression and preventing metastasis

Authors

Chirag Patel Calico Life Sciences, South San Francisco, CA, USA PubMed articles Google scholar articles
Kathleen A McGuire AbbVie Inc., North Chicago, IL, USA PubMed articles Google scholar articles
Hakimeh Ebrahimi-Nik Broad Institute of MIT and Harvard, Cambridge, MA, USA PubMed articles Google scholar articles
Meng Sun Calico Life Sciences, South San Francisco, CA, USA PubMed articles Google scholar articles
Yue Liu Calico Life Sciences, South San Francisco, CA, USA PubMed articles Google scholar articles
Kelly Klinge AbbVie Inc., North Chicago, IL, USA PubMed articles Google scholar articles
Jacqueline Aguado AbbVie Inc., North Chicago, IL, USA PubMed articles Google scholar articles
Audrey J Muscato Broad Institute of MIT and Harvard, Cambridge, MA, USA PubMed articles Google scholar articles
Payal Tiwari Broad Institute of MIT and Harvard, Cambridge, MA, USA PubMed articles Google scholar articles
Omar Avila-Monge Broad Institute of MIT and Harvard, Cambridge, MA, USA PubMed articles Google scholar articles
Kayla J Colvin Broad Institute of MIT and Harvard, Cambridge, MA, USA PubMed articles Google scholar articles
Kira Olander Broad Institute of MIT and Harvard, Cambridge, MA, USA PubMed articles Google scholar articles
Kyle Halliwill AbbVie Inc., South San Francisco, CA, USA PubMed articles Google scholar articles
Joseph Klahn AbbVie Inc., Elk Grove Village, IL, USA PubMed articles Google scholar articles
Alexander Schutte AbbVie Inc., North Chicago, IL, USA PubMed articles Google scholar articles
Marcia N Paddock Calico Life Sciences, South San Francisco, CA, USA PubMed articles Google scholar articles
Jonathan Powell Calico Life Sciences, South San Francisco, CA, USA PubMed articles Google scholar articles
Keith M Hamel AbbVie Inc., North Chicago, IL, USA PubMed articles Google scholar articles
Jennifer M Frost AbbVie Inc., North Chicago, IL, USA PubMed articles Google scholar articles
Kathleen B Yates Broad Institute of MIT and Harvard, Cambridge, MA, USA PubMed articles Google scholar articles
Philip R Kym AbbVie Inc., North Chicago, IL, USA PubMed articles Google scholar articles
Robert T Manguso Broad Institute of MIT and Harvard, Cambridge, MA, USA PubMed articles Google scholar articles
Christina K Baumgartner AbbVie Inc., North Chicago, IL, USA PubMed articles Google scholar articles

Citation

Patel C, McGuire KA, Ebrahimi-Nik H, et al

999 The PTPN2/N1 small molecule inhibitor ABBV-CLS-484 promotes NK cell activity driving primary tumor regression and preventing metastasis

Journal for ImmunoTherapy of Cancer 2023;11:doi: 10.1136/jitc-2023-SITC2023.0999

Publication history

First published November 2, 2023.

Online issue publication

November 02, 2023

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.

Log in using your username and password

Main menu

Log in using your username and password

You are here

Authors

Citation

Publication history

Request permissions

Copyright information

Read the full text or download the PDF:

Log in using your username and password